IP Library Granted Patent US 8,772,353
Granted Patent B2
US 8,772,353 · App. 13/904,818 · Granted Jul 8, 2014

Method for enhancing the bioavalability of ospemifene

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,772,353
App. No.
13/904,818
Granted
Jul 8, 2014
Kind
B2
Abstract

This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.

Claims (19)

1. A method of treating sexual dysfunction comprising orally administering a therapeutically effective amount of ospemifene or a pharmaceutically acceptable salt thereof to a patient in need thereof in connection with the intake of a foodstuff having nutritional value and causing secretion of bile acids to enhance bioavailability of the ospemifene or pharmaceutically acceptable salt thereof.

2. The method according to claim 1 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered at a time point which is in the range defined by 1 hour before starting the food intake and 2 hours after starting the food intake.

3. The method according to claim 2 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered at a time point which is in the range defined to begin at a time point during the food intake and to end 1 hour after the food intake was started.

4. The method according to claim 3 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered at a time point which is no later than 0.5 hours after starting the food intake.

5. The method according to claim 2 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered in oral dosage form and wherein the dosage amount is from 30 to 90 mg/day.

6. The method according to claim 5 wherein the dosage amount is 60 mg.

7. The method of claim 2 wherein said patient is a perimenopausal or postmenopausal woman.

8. The method according to claim 1 wherein said sexual dysfunction is dyspareunia.

9. The method according to claim 8 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered in oral dosage form and wherein the dosage amount is from 30 to 90 mg/day.

10. The method according to claim 9 wherein the dosage amount is 60 mg.

11. The method of claim 10 where said patient is a perimenopausal or postmenopausal woman.

12. The method according to claim 1 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered in oral dosage form and wherein the dosage amount is from 30 to 90 mg/day.

13. The method according to claim 12 wherein the dosage amount is 60 mg.

14. The method of claim 1 wherein said patient is a perimenopausal or a postmenopausal woman.

15. A method of treating sexual dysfunction comprising orally administering a therapeutically effective amount of ospemifene to a patient in need thereof in connection with the intake of a foodstuff having nutritional value and causing secretion of bile acids to enhance bioavailability of the ospemifene or pharmaceutically acceptable salt thereof.

16. The method according to claim 15 , wherein the ospemifene is administered at a time point which is in the range defined by 1 hour before starting the food intake and 2 hours after starting the food intake.

17. The method according to claim 15 , wherein said sexual dysfunction is dyspareunia.

18. The method according to claim 17 , wherein the dosage amount is 60 mg.

19. The method of claim 17 , wherein said patient is a perimenopausal or a postmenopausal woman.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2018
From: HORMOS MEDICAL OY
To: QUATRX PHARMACEUTICALS COMPANY
Reel/Frame 046240/0156 →
MOVABLE HYPOTHEC Recorded Apr 12, 2017
From: SHIONOGI INC.
To: DUCHESNAY INC.
Reel/Frame 042233/0807 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2014
From: ANTTILA, MARKKU
To: HORMOS MEDICAL CORPORATION
Reel/Frame 031926/0268 →
CHANGE OF NAME Recorded Jan 9, 2014
From: HORMOS MEDICAL CORPORATION
To: HORMOS MEDICAL LTD.
Reel/Frame 031950/0306 →